Literature DB >> 11122484

A strategy combining flow sorting and comparative genomic hybridization for studying genetic aberrations at different stages of colorectal tumorigenesis in ulcerative colitis.

O P Clausen1, S N Andersen, H Strøomkjaer, V Nielsen, T O Rognum, L Bolund, S Køolvraa.   

Abstract

BACKGROUND: DNA aneuploidy has been shown to increase the risk of developing dysplasia in ulcerative colitis (UC) and is related to tumorigenesis in the colorectum. Therefore, it is of particular interest to study genetic aberrations behind DNA aneuploidization during colorectal carcinogenesis. We wanted to elucidate further the relationship between mucosal morphology and DNA aberrations in UC.
METHODS: DNA flow cytometry was applied to multiple lesions including regenerative, dysplastic, and carcinomatous mucosa from the colectomy specimen of a male patient with long-standing UC. The lesions harbored multiple DNA aneuploid stemlines that were subjected to flow sorting. We analyzed gene alterations by degenerate oligonucleotide primer (DOP; universal primers) polymerase chain reaction (PCR)-based comparative genomic hybridization (CGH) and fluorescent in situ hybridization (FISH) in diploid and aneuploid sorted cells.
RESULTS: DOP-PCR-based CGH shows gains and losses that can be verified by FISH. We show that with this approach one can study genetic evolution of distinct DNA diploid and aberrant subpopulations through defined stages of colorectal tumorigenesis. This includes getting information related to tumor heterogeneity that cannot be obtained by CGH with DNA extracted from nonsorted cell populations. Genetic imbalance was also detected in diploid nondysplastic flow-sorted mucosal cells from the same bowel.
CONCLUSIONS: Similar gains and losses were found in aneuploid dysplasias and carcinomas at widely separated locations in the same bowel, indicating a common selection pressure in different areas of the same bowel. The common aberrations may be of importance for progression from dysplasia to carcinoma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11122484     DOI: 10.1002/1097-0320(20010101)43:1<46::aid-cyto1018>3.0.co;2-u

Source DB:  PubMed          Journal:  Cytometry        ISSN: 0196-4763


  6 in total

1.  Spindle proteins Aurora A and BUB1B, but not Mad2, are aberrantly expressed in dysplastic mucosa of patients with longstanding ulcerative colitis.

Authors:  E Burum-Auensen; P M Deangelis; A R Schjølberg; Jo Røislien; S N Andersen; O P F Clausen
Journal:  J Clin Pathol       Date:  2007-02-23       Impact factor: 3.411

2.  Colitis-associated colorectal cancer driven by T-bet deficiency in dendritic cells.

Authors:  Wendy S Garrett; Shivesh Punit; Carey A Gallini; Monia Michaud; Dorothy Zhang; Kirsten S Sigrist; Graham M Lord; Jonathan N Glickman; Laurie H Glimcher
Journal:  Cancer Cell       Date:  2009-09-08       Impact factor: 31.743

3.  Inverse correlation between genetic aberrations and malignancy grade in ependymal tumors: a paradox?

Authors:  H J Gilhuis; J van der Laak; P Wesseling; R H Boerman; G Beute; J L M J Teepen; J A Grotenhuis; A C Kappelle
Journal:  J Neurooncol       Date:  2004-01       Impact factor: 4.130

4.  Molecular characterization of ulcerative colitis-associated colorectal carcinomas.

Authors:  Daniela Hirsch; Julia Hardt; Christian Sauer; Kerstin Heselmeyer-Hadded; Stephanie H Witt; Peter Kienle; Thomas Ried; Timo Gaiser
Journal:  Mod Pathol       Date:  2020-12-14       Impact factor: 7.842

5.  CCL2 Promotes Colorectal Carcinogenesis by Enhancing Polymorphonuclear Myeloid-Derived Suppressor Cell Population and Function.

Authors:  Eunyoung Chun; Sydney Lavoie; Monia Michaud; Carey Ann Gallini; Jason Kim; Genevieve Soucy; Robert Odze; Jonathan N Glickman; Wendy S Garrett
Journal:  Cell Rep       Date:  2015-07-02       Impact factor: 9.423

6.  Telomere shortening correlates to dysplasia but not to DNA aneuploidy in longstanding ulcerative colitis.

Authors:  Mariann Friis-Ottessen; Laila Bendix; Steen Kølvraa; Solveig Norheim-Andersen; Paula M De Angelis; Ole Petter F Clausen
Journal:  BMC Gastroenterol       Date:  2014-01-09       Impact factor: 3.067

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.